RxDoctor Payments DataLook up a doctor →

James Krainson

Pulmonary Disease · Miami, FLNPI 1174519987

Payments from drug & device makers

$11,692,208in general payments, 2019–2025

Across 704 payments — averaging $16,608 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$10.2M
  • Pfizer$784K
  • AstraZeneca$153K
  • Merck$149K
  • Eisai Inc.$144K
  • GSK$115K
  • plus $161K from 10 others
$89,942in research payments, 2019–2025

Across 21 payments — averaging $4282.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$88K
  • GSK$1K
  • Regeneron$885

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,692,208 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Other pulmonary disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →